Health technology assessment in public health interventions: Is prevention better than cure?;La evaluación de tecnologías sanitarias en intervenciones de salud pública: ¿más vale prevenir que curar?

Gaceta Sanitaria

Volumn 25, Issue SUPPL. 1, 2011, Pages 40-48

  Espallargues, Mireia ^a,b   Pons, Joan M V ^b,c   Almazán, Caridad ^a,b   de Solà Morales, Oriol ^a,b  

^a Servei Català de la Salut CatSalut ^*  (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c GENERALITAT DE CATALUNYA   (Spain)

Author keywords

Health promotion; Health technology assessment; Interventions; Preventive medicine; Public health

Indexed keywords

ARTICLE; COMMUNITY CARE; ETHICS; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; LEGAL ASPECT; MEDICAL TECHNOLOGY; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; SAFETY; SPAIN; THEORETICAL MODEL;

BIOMEDICAL TECHNOLOGY; COMMUNITY HEALTH SERVICES; DATA COLLECTION; HEALTH PROMOTION; HUMANS; INTERVENTION STUDIES; MODELS, THEORETICAL; PREVENTIVE HEALTH SERVICES; PROGRAM EVALUATION; PUBLIC HEALTH; RESEARCH DESIGN; SAFETY MANAGEMENT; SPAIN;

EID: 80655125183     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/S0213-9111(11)70007-3     Document Type: Article

References (56)

1. Moharra M., Espallargues M., Kubesch N., et al. Systems to support health technology assessment (HTA) in member states of the European union with limited institutionalization of HTA. Int J Technol Assess Health Care 2009, 25(Suppl 2):75-83.
2. Victora C.G., Santos I.S. Los siete pecados capitales de la evaluación del impacto. Informe SESPAS 2008. Gac Sanit 2008, 22(Supl 1):1-7.
3. Esperato A., García-Altés A. Prevención en salud: ¿inversión rentable? Eficiencia económica de las intervenciones preventivas en España. Gac Sanit 2007, 21:150-161.
4. Banta H.D., de Wit G.A. Public health services and cost-effectiveness analysis. Annu Rev Public Health 2008, 29:383-397.
5. The ECHTA/ECAHI Project. Grant Agreement No. SI2.122594 (99CVF3-508). Stockholm (Sweden): The Swedish Council on Technology Assessment in Health Care (SBU); 2000.
6. Gérvas J., Starfield B., Heath I. Is clinical prevention better than cure?. Lancet 2008, 372:1997-1999.
7. Goetzel R.Z. Do prevention or treatment services save money? The wrong debate. Health Aff (Millwood) 2009, 28:37-41.
8. Segura-Benedicto A. Inducción sanitaria de los cribados: impacto y consecuencias. Aspectos éticos. Gac Sanit 2006, 20(Supl 1):88-95.
9. Guía para la elaboración de informes de evaluación de tecnologías sanitarias. Madrid: Agencia de Evaluación de Tecnologías Sanitarias (AETS); 1999.
10. Pons J.M.V., Parada I., Rius E., et al. L'avaluació de tecnologia mèdica: una eina per a la millora de la pràctica assistencial i la política sanitària i científica. Pediatr Catalana 2002, 62:39-46.
11. Velasco-Garrido M, Busse R. Health technology assessment: an introduction to objectives, role of evidence, and structure in Europe. Policy brief. Copenhagen (Denmark): European Observatory on Health Systems and Policies. WHO Regional Office for Europe; 2005.
12. Granados A. La evaluación de las tecnologías médicas. Med Clin (Barc) 1995, 104:581-585.
13. Banta D. The development of health technology assessment. Health Policy 2003, 63:121-132.
14. Higgins JPT, Green S, editores. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. Oxford (United Kingdom): The Cochrane Collaboration; 2009. [Actualizado en septiembre de 2009.] Disponible en: http://www.cochrane-handbook.org/.
15. Kemm J. The limitations of 'evidence-based' public health. J Eval Clin Pract 2006, 12:319-324.
16. Roberts H. Managing the menopause. BMJ 2007, 334:736-741.
17. Vickers M.R., MacLennan A.H., Lawton B., et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007, 335:239.
18. Nebot M. Speaker's corner. Health promotion evaluation and the principle of prevention. J Epidemiol Community Health 2006, 60:5-6.
19. Nebot M. Evaluación en salud pública: ¿todo vale?. Gac Sanit 2007, 21:95-96.
20. Peiró S. Comentario: complejidades en la evaluación de intervenciones complejas. Gac Sanit 2005, 19:234-237.
21. Ukoumunne O.C., Gulliford M.C., Chinn S., et al. Methods in health service research. Evaluation of health interventions at area and organisation level. BMJ 1999, 319:376-379.
22. Holland W.W. Health technology assessment and public health: a commentary. Int J Technol Assess Health Care 2004, 20:77-80.
23. Victora C.G., Habicht J.P., Bryce J. Evidence-based public health: moving beyond randomized trials. Am J Public Health 2004, 94:400-405.
24. Des J., Lyles C., Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004, 94:361-366.
25. Banta H.D. Considerations in defining evidence for public health: the European Advisory Committee on Health Research World Health Organization Regional Office for Europe. Int J Technol Assess Health Care 2003, 19:559-572.
26. Rychetnik L., Frommer M., Hawe P., et al. Criteria for evaluating evidence on public health interventions. J Epidemiol Community Health 2002, 56:119-127.
27. Ray W.A. Policy and program analysis using administrative databases. Ann Intern Med 1997, 127:712-718.
28. Sackett D.L., Wennberg J.E. Choosing the best research design for each question. BMJ 1997, 315:1636.
29. Campbell M., Fitzpatrick R., Haines A., et al. Framework for design and evaluation of complex interventions to improve health. BMJ 2000, 321:694-696.
30. Márquez-Calderón S. Los efectos negativos de las intervenciones preventivas basadas en el individuo. Informe SESPAS 2008. Gac Sanit 2008, 22(Supl 1):205-215.
31. Stewart-Brown S., Farmer A. Screening could seriously damage your health. BMJ 1997, 314:533-534.
32. Gray J.A. New concepts in screening. Br J Gen Pract 2004, 54:292-298.
33. Haynes R.B., Sackett D.L., Taylor D.W., et al. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978, 299:741-744.
34. Jennings D., Netsky M.G. Essential hypertension: a sign in search of a disease. CMAJ 1991, 144:973-979.
35. Callahan D. El bien individual y el bien común en bioética 2009, Cuadernos de la Fundació Víctor Grífols i Lucas, Barcelona, 23-4.
36. Permanyer G ¿Son valores antagónicos la prevención y la compasión?. Med Clin (Barc) 2010, 135:650-652.
37. Gérvas J. Moderación en la actividad médica preventiva y curativa. Cuatro ejemplos de necesidad de prevención cuaternaria en España. Gac Sanit. 2006, 20(Supl 1):127-134.
38. Marrugat J., Sala J., Elosua R., et al. Prevención cardiovascular: avances y el largo camino por recorrer. Rev Esp Cardiol 2010, 63(Supl 2):49-54.
39. Wilson R.M. Screening for breast and cervical cancer as a common cause for litigation. A false negative result may be one of an irreducible minimum of errors. BMJ 2000, 320:1352-1353.
40. Getz L., Sigurdsson J.A., Hetlevik I. Is opportunistic disease prevention in the consultation ethically justifiable?. BMJ 2003, 327:498-500.
41. Quanstrum K.H., Hayward R.A. Lessons from the mammography wars. N Engl J Med 2010, 363:1076-1079.
42. Welch H.G. Screening mammography -- a long run for a short slide?. N Engl J Med 2010, 363:1276-1278.
43. Jorgensen K.J., Brodersen J., Hartling O.J., et al. Informed choice requires information about both benefits and harms. J Med Ethics 2009, 35:268-269.
44. Gotzsche P.C., Hartling O.J., Nielsen M., et al. Breast screening: the facts -- or maybe not. BMJ 2009, 338:b86.
45. Brodersen J., Jorgensen K.J., Gøtzsche P.C. The benefits and harms of screening for cancer with a focus on breast screening. Pol Arch Med Wewn 2010, 120:89-94.
46. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD001877. DOI: 10.1002/14651858.CD001877.pub4.
47. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985, 14:32-38.
48. Sánchez E. El principio de precaución: implicaciones para la salud pública. Gac Sanit 2002, 16:371-373.
49. Public health: ethical issues. London (United Kingdom): Nuffield Council on Bioethics; 2007.
50. Subías P.J., Perula L., Moreno J., et al. Encuesta a la población para valoración y conocimiento de su percepción sobre actividades preventivas. Aten Primaria 2003, 32:5-14.
51. U.S. Preventive Services Task Force (USPSTF) [página en Internet]. Rockville, MD (US): Agency for Healthcare Research and Quality. Disponible en: http://www.ahrq.gov/clinic/uspstfix.htm.
52. Canadian Task Force on Preventive Health Care [página en Internet]. Ottawa, ON (Canada): Canadian Task Force on Preventive Health Care. Disponible en: http://www.canadiantaskforce.ca/.
53. Chaulk C.P., Kazandjian V.A., Vallejo P. Evaluación en salud pública: lecciones aprendidas de la gestión de la tuberculosis pulmonar. Gac Sanit 2008, 22:362-370.
54. Kurth R. Public health and civil liberties. Introduction to the talking point on public health versus civil liberties. EMBO Rep 2007, 8:1091-1092.
55. Sackett D.L. The arrogance of preventive medicine. CMAJ 2002, 167:363-364.
56. De Solà-Morales O., Granados A. Health technology assessment in Catalonia: an overview of past and future perspectives. Int J Technol Assess Health Care 2009, 25(Suppl 1):88-93.